Skip to main content

Advertisement

Table 3 Pharmacological characterization of spotted gar fabp1 promoter PPRE mutants

From: Subfunctionalization of peroxisome proliferator response elements accounts for retention of duplicated fabp1 genes in zebrafish

  WY14643
  Upward Slope Downward Slope
  No mutation ΔPPRE-1 ΔPPRE-2 No mutation ΔPPRE-1 ΔPPRE-2
E max (RLU) 101 ± 2.56 70.6 ± 2.17* 102 ± 8.65 - - -
E min (RLU) 1.32 ± 2.91 –1.64 ± 3.08 –17.4 ± 18.2 27.6 ± 4.76** - -
EC50 (μM) 0.013 (0.004–0.023) 0.045 (0.032–0.064)* 0.028 (0.008–0.098) 0.38 (0.20–0.41)** - -
  Rosiglitazone
  Upward Slope Downward Slope
  No mutation ΔPPRE-1 ΔPPRE-2 No mutation ΔPPRE-1 ΔPPRE-2
E max (RLU) 64.9 ± 2.34 61.9 ± 6.66 62.1 ± 5.07 - - -
E min (RLU) −7.47 ± 3.79 1.17 ± 0.05 2.94 ± 4.03 - - -
EC50 (μM) 0.008 (0.003–0.019) 0.003 (0.001–1.34) 0.18 (0.08–0.36)* - - -
  1. Data derived from Fig. 6 presented as the mean ± SEM or 95 % confidence intervals (brackets)
  2. *P < 0.05 compared to agonist treatment alone within the upward slope
  3. **P < 0.05 compared to matched treatment between upward and downward slopes, as determined via two-way ANOVA followed by Bonferroni’s post-hoc analysis for E max, E min, or by non-overlapping confidence intervals (EC50). n = 3